Drugs for Parkinson's disease

Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32.
No abstract available

Keywords: Apokyn; Aricept; Azilect; Clozaril; Cogentin; Comtan; Duodopa; Duopa; Ebixa; Eldepryl; Exelon; Gocovri; Inbrija; Kynmobi; Lodosyn; Mirapex; Movapo; Namenda; Neupro; Nourianz; Nuplazid; Ongentys; Onstryv; Osmolex; Parkinson's disease; Parlodel; Razadyne; Requip; Rytary; SNRIs; SSRIs; Seroquel; Sinemet; Stalevo; Tasmar; Xadago; Zelapar; Zofran; adverse effects; amantadine; apomorphine; benztropine; bromocriptine; carbidopa; carbidopa/levodopa; clozapine; deep brain stimulation; depression; donepezil; dosage; drug interactions; efficacy; entacapone; galantamine; istradefylline; levodopa; memantine; nortriptyline; ondansetron; opicapone; pimavanserin; pramipexole; quetiapine; rasagiline; rivastigmine; ropinirole; rotigotine; safety; safinamide; selegiline; tolcapone; trihexyphenidyl.

Publication types

  • Review

MeSH terms

  • Antiparkinson Agents / administration & dosage*
  • Antiparkinson Agents / pharmacokinetics
  • Carbidopa / administration & dosage
  • Carbidopa / pharmacokinetics
  • Catechol O-Methyltransferase / metabolism
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / metabolism
  • Dopaminergic Neurons / pathology
  • Drug Therapy, Combination
  • Humans
  • Levodopa / administration & dosage
  • Levodopa / pharmacokinetics
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / psychology

Substances

  • Antiparkinson Agents
  • Levodopa
  • COMT protein, human
  • Catechol O-Methyltransferase
  • Carbidopa